SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 5, 2000 (March 30, 2000)
MAXXIM MEDICAL, INC.
------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Texas 0-18208 76-0291634
---------------------------- ----------- -------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
10300 49th Street North, Clearwater, FL 33762
---------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (727) 561-2100
<PAGE>
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
Maxxim Medical, Inc. ("Maxxim"), with the approval of its Board of
Directors, dismissed KPMG LLP (the "Former Accountants") and appointed Arthur
Andersen LLP (the "New Accountants") as independent accountants of Maxxim and
its subsidiaries, effective March 30, 2000. Maxxim Medical Group, Inc., a
wholly-owned subsidiary of Maxxim, is the issuer under a registration statement
to exchange the unregistered senior subordinated discount notes issued in
connection with a recapitalization of Maxxim.
The Former Accountants' audit reports on Maxxim's consolidated
financial statements as of and for the fiscal years ended October 31, 1999, and
November 1, 1998 did not contain an adverse opinion or disclaimer of opinion,
nor were they qualified or modified as to uncertainty, audit scope or accounting
principles. In connection with the audits of Maxxim as of and for the fiscal
years ended October 31, 1999, and November 1, 1998, and the subsequent period
through March 31, 2000, there were no disagreements with the Former Accountants
on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure, which disagreements, if not resolved
to the satisfaction of the Former Accountants, would have caused the Former
Accountants to make reference in connection with their opinion to the subject
matter of disagreement and there did not occur any of the events listed in Item
304(a)(2) of Regulation S-K.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(a) Exhibits
Letter of KPMG LLP to the Securities and Exchange Commission included herein
pursuant to the requirements of Item 304(a)(3) of Regulation S-K.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MAXXIM MEDICAL, INC.
Dated: April 5, 2000 By: /s/ Kenneth W. Davidson
------------------------- -------------------------------
By: Kenneth W. Davidson
Title: Chairman of the Board
President and Chief
Executive Officer
Dated: April 5, 2000 By: /s/ Alan S. Blazei
------------------------- --------------------------
By: Alan S. Blazei
Title: Executive Vice President,
Controller and Treasurer
<PAGE>
EXHIBIT INDEX
Page No.
Letter dated April 5, 2000, from KPMG LLP to the Securities
& Exchange Commission. 5
